IQVIA Holdings Inc. (NYSE:IQV) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on IQVIA Holdings Inc. (NYSE:IQV) to $215 from $266 on February 23, reiterating an Outperform rating on the shares and updating its model on the company after the fiscal Q4 report. Truist also lowered the price target on the stock to $245 from $290 on February 19. It maintained a Buy rating on the shares, telling investors that it is updating its model on IQVIA Holdings Inc. (NYSE:IQV) a ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnshul Thakral - CEO and DirectorDavid Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorJailendra Singh - Managing DirectorJill McConnell - CFOTracy Krumme - SVP of Investor RelationsConference Call ParticipantsAnn Hynes - AnalystEric Coldwell - Senior Research AnalystJustin Bowers - Biopharma Services Senior Equity Research AnalystMax Smock - AnalystPatrick Donnelly - Managing Director and ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnshul Thakral - CEO and DirectorDavid Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorJailendra Singh - Managing DirectorJill McConnell - CFOTracy Krumme - SVP of Investor RelationsConference Call ParticipantsAnn Hynes - AnalystEric Coldwell - Senior Research AnalystJustin Bowers - Biopharma Services Senior Equity Research AnalystMax Smock - AnalystPatrick Donnelly - Managing Director and ...

Fortrea (NasdaqGS:FTRE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker9Good day. Thank you for standing by. Welcome to the Fortrea Q4 and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated message advising your hand is raised. To withdraw your question ...

Learn more at fortrea.com. ©2026 Fortrea Inc. All rights reserved. Fortrea Q4'2025 Earnings presentation Q4 & FY 2025 Earnings Presentation 02.26.2026 Nasdaq: FTRE Learn more at fortrea.com. ©2026 Fortrea Inc. All rights reserved. Fortrea Q4'2025 Earnings presentation FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements Disclosure. Certain information in this presentation contains "forward-looking" statements. You should not place undue reliance on these statements. Forward- l ...

Core Viewpoint - ICON Public Limited Company is under investigation for potential violations of federal securities laws following a significant decline in shareholder value due to a revenue overstatement disclosure and a delay in earnings release [1][2][3]. Financial Performance and Market Reaction - The company's single-day stock decline resulted in the loss of billions of dollars in shareholder value, marking one of the largest percentage drops in the Contract Research Organization (CRO) sector in recent years [2]. - Prior to the disclosure, ICON's stock reflected investor confidence, with a consensus revenue range of $8.05 billion to $8.1 billion and adjusted EPS guidance of $13.00 to $13.20 for full-year 2025 [2]. - The abrupt sell-off indicated that the market had not anticipated risks related to revenue overstatement or delays in earnings release [2]. Revenue Overstatement and Earnings Delay - ICON disclosed a preliminary revenue overstatement of under two percent per year for fiscal years 2023 and 2024, along with a delay in releasing Q4 and full-year 2025 results [3]. - CEO Barry Balfe had previously assured investors that the company's performance was "broadly in line with expectations" [3]. - CFO Nigel Clerkin reported Q3 2025 revenue of $2.043 billion, reflecting a year-over-year increase of 0.6 percent, based on figures now under scrutiny [3]. Stock Buyback and Future Guidance - In the quarters leading up to the disclosure, ICON repurchased $750 million of its own stock and had a new $1 billion buyback authorization, indicating confidence in its financial position [4]. - A filing on January 7, 2026, indicated that full-year 2026 guidance would be released alongside the delayed Q4 and full-year 2025 results, which is now uncertain due to the delay [4].

Core Viewpoint - Medpace Holdings, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price despite reporting strong Q4 earnings [1][2]. Financial Performance - Medpace reported Q4 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding Wall Street consensus estimates [2]. - The stock price fell approximately 10% by mid-day and closed down 15.9%, with a trading volume of about $10.2 million during the sell-off, indicating heightened trading activity [2]. Market Reaction - Analysts attributed the stock decline to a bookings shortfall, which overshadowed the positive sales and profit figures [3]. - The book-to-bill ratio missed expectations, leading to concerns about forward demand and a sharp decline in stock price [3]. Institutional Activity - Principal Financial Group reduced its stake in Medpace by 8.4% prior to the earnings release, while Representative David Taylor purchased shares shortly before [4]. Analyst Inquiries - During the Q4 earnings call, analysts raised concerns about booking deterioration and cancellation levels, with management indicating that cancellations were at the highest level compared to the previous year [5]. - The CEO described cancellations as "broad-based" without providing clear answers on the causes, leaving investors uncertain [5].

Charles River Laboratories (NYSE:CRL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsBirgit Girshick - EVP and COOCasey Woodring - VP, Equity ResearchDave Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorEric Coldwell - Managing DirectorJames Foster - Chair, President and CEOLuke Sergott - Director - Healthcare Equity ResearchMichael Knell - VP and Chief Financial OfficerMichael Ryskin - Managing DirectorTodd Spencer - VP of Investor RelationsConference Call P ...

Charles River Laboratories (NYSE:CRL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsBirgit Girshick - EVP and COOCasey Woodring - VP, Equity ResearchDave Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorEric Coldwell - Managing DirectorJames Foster - Chair, President and CEOLuke Sergott - Director - Healthcare Equity ResearchMichael Knell - VP and Chief Financial OfficerMichael Ryskin - Managing DirectorTodd Spencer - VP of Investor RelationsConference Call P ...

Charles River Laboratories 4Q 2025 Results & 2026 Guidance February 18, 2026 Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends o ...